Enterprise Value
431.8M
Cash
345M
Avg Qtr Burn
-18.2M
Short % of Float
8.56%
Insider Ownership
4.03%
Institutional Own.
98.14%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zanidatamab (HER2) Details Cancer, Solid tumor/s, Biliary Tract Cancer | PDUFA Approval decision | |
Zanidatamab (HER2) Details Cancer, Cholangiocarcinoma, Gastroesophageal adenocarcinomas | Phase 3 Data readout | |
Zanidatamab + Chemo/trastuzumab Details Breast cancer, Cancer, HER2-expressing cancers | Phase 3 Initiation | |
Zanidatamab (HER2) + chemotherapy + tislelizumab Details Cancer, Gastroesophageal adenocarcinomas, Cholangiocarcinoma | Phase 2 Update | |
Zanidatamab zovodotin (ZW49) Details HER2-expressing cancers, Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Zanidatamab (HER2) + docetaxel Details Cancer, Breast cancer | Phase 1/2 Data readout | |
ZW191 Details Cancer | Phase 1 Initiation | |
ZW171 Details Cancer, Mesothelin-expressing solid tumors | Phase 1 Initiation | |
ZW251 (GPC3 ADC) Details Cancer | IND Submission | |
ZW220 (NaPi2b ADC) Details Cancer | IND Submission |